Search Result

Isoforms Recommended:	Axl

Results for "

Axl

" in MedChemExpress (MCE) Product Catalog:

By Targets:	TAM Receptor (94) ADC Antibody (3) Akt (4) Anaplastic lymphoma kinase (ALK) (3) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (19) Autophagy (3) Bacterial (1) c-Fms (4) c-Kit (7) c-Met/HGFR (31) Discoidin Domain Receptor (5) Drug Isomer (1) E1/E2/E3 Enzyme (1) EGFR (1) ERK (2) Fat Mass and Obesity-associated Protein (FTO) (1) FGFR (3) FLT3 (20) Hedgehog (1) HIF/HIF Prolyl-Hydroxylase (3) IGF-1R (4) Isotope-Labeled Compounds (4) JAK (2) MHC (2) MMP (1) p38 MAPK (2) PDGFR (2) PI3K (2) PROTACs (2) Reference Standards (12) RIP kinase (1) ROS Kinase (3) SARS-CoV (1) Small Interfering RNA (siRNA) (3) Src (1) STAT (1) Survivin (1) TGF-β Receptor (1) Tie (1) Trk Receptor (4) VEGFR (18) VSV (1) YAP (4)
By Research Areas:	Cancer (118) Cardiovascular Disease (4) Endocrinology (3) Infection (4) Inflammation/Immunology (13) Metabolic Disease (1) Neurological Disease (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

127

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: TAM Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12432

Gilteritinib 40+ Cited Publications ASP2215	FLT3 TAM Receptor	Cancer
Gilteritinib (ASP2215) is a potent and ATP-competitive *FLT3/AXL* inhibitor with IC₅₀s of 0.29 nM/0.73 nM, respectively.

HY-15150

Bemcentinib Maximum Cited Publications 62 Publications Verification R428; BGB324	TAM Receptor	Cancer
Bemcentinib (R428) is a selective and orally active *Axl* inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

HY-15494

Picropodophyllin 25+ Cited Publications Axl1717; Picropodophyllotoxin; PPP	IGF-1R Apoptosis	Endocrinology Cancer
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-114166

2-D08 10+ Cited Publications	E1/E2/E3 Enzyme TAM Receptor	Cancer
2-D08 is a cell permeable, mechanistically unique inhibitor of protein SUMOylation. 2-D08 also inhibits *Axl* with an IC₅₀ of 0.49 nM.

HY-138696

Zanzalintinib 1 Publications Verification XL092	TAM Receptor c-Met/HGFR VEGFR	Cancer
Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, *AXL* and MER, with IC₅₀s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research .

HY-16961

Sitravatinib 5+ Cited Publications MGCD516; MG-516	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-12044

Cabozantinib S-malate 55+ Cited Publications XL184 S-malate; BMS-907351 S-malate	VEGFR Apoptosis	Cancer
Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, *Axl* and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-117596

UNC569 2 Publications Verification	TAM Receptor	Cancer
UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC₅₀ of 2.9 nM and a K_i of 4.3 nM. UNC569 also inhibits *Axl* and Tyro3 with IC₅₀s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research

HY-12963

Dubermatinib 5+ Cited Publications TP-0903	TAM Receptor Apoptosis	Cancer
Dubermatinib (TP-0903) is a potent and selective *Axl* receptor tyrosine kinase inhibitor with an IC₅₀ value of 27 nM.

HY-12432A

Gilteritinib hemifumarate 40+ Cited Publications ASP2215 hemifumarate	FLT3 TAM Receptor	Cancer
Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive *FLT3/AXL* inhibitor with IC₅₀ of 0.29 nM/0.73 nM, respectively.

HY-15797

UNC2250 4 Publications Verification	TAM Receptor	Cancer
UNC2250 is a potent and selective Mer inhibitor with an IC₅₀ of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.

HY-12494

LDC1267 5+ Cited Publications	TAM Receptor	Inflammation/Immunology Cancer
LDC1267 is a highly selective *TAM (Tyro3, Axl* and Mer) kinase inhibitor with IC₅₀*s of <5 nM/8 nM/29 nM for Tyro3,Axl* and Mer respectively .

HY-152830

Adrixetinib Q702	c-Fms TAM Receptor MHC	Cancer
Adrixetinib (Q702) is an orally active triple inhibitor against CSF1R, Mer, and *Axl, with K_d* values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma .

HY-107145A

Ningetinib 1 Publications Verification	TAM Receptor VEGFR c-Met/HGFR	Cancer
Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and *Axl*, respectively.

HY-114358

Tamnorzatinib 2 Publications Verification ONO-7475	TAM Receptor Trk Receptor	Cancer
Tamnorzatinib (ONO-7475) is a potent, selective, and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. Tamnorzatinib sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. Tamnorzatinib combines with Osimertinib (HY-15772) provides a bright promise for the study of EGFR-mutated non-small cell lung cancer (NSCLC).

HY-100946

CEP-40783 2 Publications Verification RXDX-106	TAM Receptor c-Met/HGFR	Cancer
CEP-40783 is a potent, selective and orally available inhibitor of *AXL* and c-Met with IC₅₀ values of 7 nM and 12 nM, respectively.

HY-132200

UNC5293	TAM Receptor Anaplastic lymphoma kinase (ALK) FLT3	Cancer
UNC5293 is a MERTK-selective and potent inhibitor (K_i=190 pM). UNC5293 inhibits MERTK (IC₅₀=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research .

HY-13016S

Cabozantinib-d6 XL184-d₆; BMS-907351-d₆	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .

HY-173268

UNC9426	TAM Receptor	Cardiovascular Disease Cancer
UNC9426 is a potent and selective TYRO3 inhibitor (IC₅₀ = 2.1 nM), demonstrating 276-fold and 90-fold selectivity over MERTK and AXL, respectively. UNC9426 reduces platelet aggregation without increasing bleeding time and blocks TYRO3-dependent functions in tumor cells and macrophages. UNC9426 demonstrates a favorable safety profile with no significant increase in bleeding risk in vivo. UNC9426 can be used for functional studies of TYRO3-dependent phenotypes such as non-small cell lung cancer (NSCLC) .

HY-P99463

Batiraxcept 2 Publications Verification AVB-500; AVB-S6-500	TAM Receptor PI3K Akt p38 MAPK	Cancer
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((K_D <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .

HY-100509

NPS-1034 1 Publications Verification	TAM Receptor c-Met/HGFR Apoptosis	Cancer
NPS-1034 is a dual inhibitor of *AXL* and MET with IC₅₀s of 10.3 and 48 nM, respectively.

HY-12965

S49076 1 Publications Verification	FGFR c-Met/HGFR	Cancer
S49076 is a novel, potent inhibitor of MET, *AXL/MER, and FGFR1/2/3* with IC₅₀ values below 20 nM.

HY-12964

SGI-7079 3 Publications Verification	TAM Receptor	Cancer
SGI-7079 is a selective, ATP-competitive, orally active inhibitor of the receptor tyrosine kinase Axl. SGI-7079 blocks Axl-mediated signaling pathways such as NF-κB activation and MMP-9 expression, thereby inhibiting tumor cell proliferation, migration and invasion. SGI-7079 is mainly used in the research of malignant tumors such as inflammatory breast cancer and bladder cancer, as well as in combination with immunization (used in combination with PD-1 therapy)[1][2][3].

HY-147218

PF-07265807	c-Met/HGFR TAM Receptor	Cancer
PF-07265807 is a potent TAM and c-Met kinase inhibitor with IC₅₀ values of 6.1 nM, 13.2 nM and 21.6 nM for AXL, MER and TYRO3, respectively. PF-07265807 can be used for researching anticancer .

HY-119933

RIPK1-IN-7	RIP kinase	Cancer
RIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a K_d of 4 nM and an enzymatic IC₅₀ of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model .

HY-P99360

Enapotamab Anti-Axl/UFO Reference Antibody (enapotamab)	TAM Receptor ADC Antibody	Cancer
Enapotamab (Anti-AXL/UFO Reference Antibody) is an AXL/UFO-related antibody that can be used for synthesis of ADC molecule Enapotamab vedotin (HY-P99921) .

HY-145622

Mecbotamab vedotin BA3011; CAB-Axl-ADC; CAB-anti-Axl-ADC	Antibody-Drug Conjugates (ADCs) TAM Receptor	Cancer
Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting *AXL. Mecbotamab vedotin can significantly inhibit AXL* in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Monomethyl auristatin E (MMAE) (HY-15162) .

HY-114357A

DS-1205b free base	TAM Receptor c-Met/HGFR Trk Receptor	Cancer
DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC₅₀ of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC₅₀s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo .

HY-P99161

Tilvestamab BGB149	TAM Receptor	Cancer
Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks *AXL*-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced *AXL* activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in *AXL* overexpressing renal cell carcinomas .

HY-132893

AZ14145845	TAM Receptor	Cancer
AZ14145845 is a highly selective type I1/2 dual *Mer/Axl* kinase inhibitor with in vivo efficacy.

HY-114356

BPI-9016M	c-Met/HGFR	Cancer
BPI-9016M is a potent, orally active, and selective dual c-Met and *AXL* tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma .

HY-144627

*PROTAC Axl* Degrader 2**	PROTACs TAM Receptor	Cancer
PROTAC Axl Degrader 2 is a potent and selective PROTAC Axl degrader with an IC₅₀ of 1.61 μM. PROTAC Axl Degrader 2 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degrader 2 induces mehuosis .

HY-15494R

Picropodophyllin (Standard) Axl1717 (Standard); Picropodophyllotoxin (Standard); PPP (Standard)	IGF-1R Apoptosis Reference Standards	Endocrinology Cancer
Picropodophyllin (Standard) is the analytical standard of Picropodophyllin. This product is intended for research and analytical applications. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

HY-155310

AF-2112	YAP	Cancer
AF-2112 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2.

HY-176205

Ligritinib AB801	TAM Receptor	Cancer
Ligritinib (AB801) is an orally active *AXL* receptor tyrosine kinase inhibitor. Ligritinib blocks the downstream signaling pathway by inhibiting the kinase activity of AXL. Ligritinib can be used in cancer research, especially in combination with chemotherapy for non-small cell lung cancer (NSCLC) .

HY-155309

LM-41	YAP	Cancer
LM-41 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2. LM-41 inhibits migration of human MDA-MB-231 breast cancer cells .

HY-115778

UNC3133	TAM Receptor FLT3	Inflammation/Immunology Cancer
UNC3133 is an orally active, limitedly selective MerTK inhibitor with an IC₅₀ of 3.0 nM. UNC3133 inhibits *Axl, Tyro3* and Flt3 kinases, with IC₅₀ values of 17 nM, 31 nM and 6.8 nM, respectively. UNC3133 is applicable to the research of inflammatory diseases and cancers .

HY-12432R

Gilteritinib (Standard) ASP2215 (Standard)	Reference Standards FLT3 TAM Receptor	Cancer
Gilteritinib (Standard) is the analytical standard of Gilteritinib. This product is intended for research and analytical applications. Gilteritinib (ASP2215) is a potent and ATP-competitive *FLT3/AXL* inhibitor with IC₅₀s of 0.29 nM/0.73 nM, respectively.

HY-P9988

Mecbotamab BA301	ADC Antibody TAM Receptor	Cancer
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .

HY-13016S1

Cabozantinib-d4 XL184-d₄; BMS-907351-d₄	VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis	Cancer
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-151904

AXL-IN-13	TAM Receptor FLT3 PDGFR	Cancer
AXL-IN-13 is a potent and orally active *AXL* inhibitor (IC₅₀: 1.6 nM, K_d: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion .

HY-144624

*PROTAC Axl* Degrader 1**	PROTACs TAM Receptor	Cancer
PROTAC Axl Degrader 1 is a potent and selective PROTAC Axl degrader with an IC₅₀ of 0.92 μM. PROTAC Axl Degrader 1 shows anti-proliferation activity, anti-migration activity in vitro. PROTAC Axl Degrader 1 induces mehuosis .

HY-P99921

Enapotamab vedotin HuMax-Axl-ADC	Antibody-Drug Conjugates (ADCs) TAM Receptor	Cancer
Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC). Enapotamab vedotin also exhibits resistant to EGFR inhibitor such as Osimertinib (HY-15772) .

HY-124502

UNC4203	TAM Receptor FLT3	Cancer
UNC4203 is a potent, orally available and highly selective MERTK inhibitor, with IC₅₀s of 1.2 nM, 140 nM, 42 nM and 90 nM for MERTK, AXL, TYRO3 and FLT3, respectively .

HY-177332

SLC-391	TAM Receptor SARS-CoV Akt	Infection Cancer
SLC-391 is an orally active *AXL* kinase inhibitor with an IC₅₀ of 9.6 nM against *AXL* kinase. SLC-391 inhibits Gas6-induced AXL-dependent phosphorylation of Akt. SLC-391 inhibits SARS-CoV-2 infection, entry and replication in cells. SLC-391 suppresses cancer cell proliferation. SLC-391 inhibits tumor growth in mouse solid tumor xenograft models. SLC-391 can be used for the research of COVID-19, influenza virus infection, triple-negative breast cancer, chronic myeloid leukemia and non-small cell lung cancer .

HY-179105

Axl-IN-20	TAM Receptor	Cancer
Axl-IN-20 (Compound w11) is a selective, orally active *AXL* inhibitor, with an IC₅₀ of 5 nM. Axl-IN-20 has antitumor activity against hematological malignancies .

HY-153012

Axl/Mer/CSF1R-IN-1	TAM Receptor c-Fms	Cancer
Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with K_ds of <0.1 μM .

HY-144706

Axl-IN-3	TAM Receptor	Cancer
Axl-IN-3 is a potent, selective and orally active AXL kinase inhibitor with an IC₅₀ of 41.5 nM. Axl-IN-3 has lower inhibition of other kinases .

HY-176204

Axl-IN-19	TAM Receptor	Cancer
Axl-IN-19 (Compound 68) is a selective *AXL* (a membrane-bound receptor tyrosine kinase) inhibitor (IC₅₀: 5.3 nM; Cellular K_D = 6.8 nM). Axl-IN-19 has favorable rat PK with low clearance and moderate bioavailability. Axl-IN-19 can be used for cancer research .

HY-16961A

Sitravatinib malate MGCD516 malate; MG-516 malate	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

Cat. No.	Product Name	Type

HY-145622

Mecbotamab vedotin

BA3011; CAB-Axl-ADC; CAB-anti-Axl-ADC

Fluorescent Dye

Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting AXL. Mecbotamab vedotin can significantly inhibit AXL in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Monomethyl auristatin E (MMAE) (HY-15162) .

HY-15150G

Bemcentinib (GMP)

R428 (GMP); BGB324 (GMP)

Fluorescent Dye

Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

Cat. No.	Product Name	Type

HY-15150G

Bemcentinib (GMP)

R428 (GMP); BGB324 (GMP)

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P1790

Axltide	JAK	Metabolic Disease
Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases .

HY-P5527F

FAM-CSKtide	Peptides	Others
FAM-CSKtide is a biological active peptide. (This is a FAM labeled peptide substrate (Abs/Em = 494/521 nm) for C-terminal Src kinase (Csk) and many other kinases such as Axl, cKit, ERBB4, Fes, Flt3, IGF-1 R, MET, MUSK, PYK2, Ret, TIE2, TrkA, VEGF-R1 and VEGF-R2.)

Cat. No.	Product Name	Target	Research Area	Image

HY-P99463

Batiraxcept 2 Publications Verification AVB-500; AVB-S6-500	TAM Receptor PI3K Akt p38 MAPK	Cancer
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((K_D <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .

HY-P99360

Enapotamab Anti-Axl/UFO Reference Antibody (enapotamab)	TAM Receptor ADC Antibody	Cancer
Enapotamab (Anti-AXL/UFO Reference Antibody) is an AXL/UFO-related antibody that can be used for synthesis of ADC molecule Enapotamab vedotin (HY-P99921) .

HY-P99161

Tilvestamab BGB149	TAM Receptor	Cancer
Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks *AXL*-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced *AXL* activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in *AXL* overexpressing renal cell carcinomas .

HY-P9988

Mecbotamab BA301	ADC Antibody TAM Receptor	Cancer
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .

HY-P99921

Enapotamab vedotin HuMax-Axl-ADC	Antibody-Drug Conjugates (ADCs) TAM Receptor	Cancer
Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC). Enapotamab vedotin also exhibits resistant to EGFR inhibitor such as Osimertinib (HY-15772) .

HY-P991664

AG01	Src Akt ERK TAM Receptor c-Met/HGFR MMP HIF/HIF Prolyl-Hydroxylase VEGFR	Cancer
AG01 is a monoclonal antibody against progranulin (GP88). AG01 inhibits triple-negative breast cancer (TNBC) cell proliferation and migration, reduces the expression of phosphorylated protein kinases p-Src, p-AKT, and p-ERK, and reduces the expression of oncogenic proteins such as *Axl, c-MET, HIF-1α, and VEGF*. AG01 inhibits tumor growth and Ki67 expression in a TNBC xenograft mouse model. AG01 can be used in the research of TNBC and other cancers .

HY-P99733

Mipasetamab	ADC Antibody TAM Receptor	Cancer
Mipasetamab is an IgG1κ antibody targeting to *AXL, a tyrosine kinase receptor* and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .

HY-P990339

*Anti-AXL/UFO Antibody (ORY012)* ORY012	Inhibitory Antibodies	Inflammation/Immunology
Anti-AXL/UFO Antibody (ORY012) is a humanized antibody expressed in CHO cells, targeting *AXL/UFO. Anti-AXL/UFO Antibody (ORY012) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.78 kDa. The isotype control for Anti-AXL*/UFO Antibody (ORY012) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15494

Picropodophyllin 25+ Cited Publications Axl1717; Picropodophyllotoxin; PPP	Classification of Application Fields Lignans Dysosma versipellis (Hance) M. Cheng ex Ying Phenylpropanoids Plants Berberidaceae Disease Research Fields Endocrinology Source Classification	IGF-1R Apoptosis
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-15494R

Picropodophyllin (Standard) Axl1717 (Standard); Picropodophyllotoxin (Standard); PPP (Standard)	Structural Classification Lignans Dysosma versipellis (Hance) M. Cheng ex Ying Phenylpropanoids Plants Berberidaceae Source Classification	IGF-1R Apoptosis Reference Standards
Picropodophyllin (Standard) is the analytical standard of Picropodophyllin. This product is intended for research and analytical applications. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

HY-N12041

Axl-IN-16	Natural Products Microorganisms Source Classification	TAM Receptor HIF/HIF Prolyl-Hydroxylase
Axl-IN-16 is a dual inhibitor of *Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl*-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

HY-N3634

Corylifol C	Leguminosae Phenols Polyphenols Psoralea corylifolia L. Plants Source Classification	EGFR TAM Receptor Tie
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

Recombinant Proteins Recommended:

Species:	Human (10) Mouse (2) Cynomolgus (1)
Tag:	His (8) Avi (4) Flag (1) Fc (5)
Source:	HEK293 (12) Sf9 insect cells (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P77567

	AXL Protein, Cynomolgus (HEK293, His) Axl; UFO; Axl oncogene; Axl; ARK; JTK11; Tyro7; AI323647; EC 2.7.10; EC 2.7.10.1	Cynomolgus	HEK293
	AXL Protein, a receptor tyrosine kinase, mediates signals by binding GAS6, regulating cell survival, proliferation, migration, and differentiation. Upon ligand binding, AXL undergoes dimerization and autophosphorylation, activating downstream molecules like PI3-kinase subunits, GRB2, PLCG1, and more. This triggers AKT kinase activation, influencing processes such as endothelial cell survival, cytokine signaling in NK cell development, hepatic regeneration, gonadotropin-releasing hormone neuron function, platelet activation, thrombotic responses, and immune modulation. AXL also serves as a receptor for lassa virus and lymphocytic choriomeningitis virus during microbial infection. AXL Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived AXL protein, expressed by HEK293 , with C-His labeled tag.

HY-P77876

	AXL Protein, Human (Biotinylated, HEK293, Fc) Axl; UFO; Axl oncogene; Axl; ARK; JTK11; Tyro7; AI323647; EC 2.7.10; EC 2.7.10.1	Human	HEK293
	AXL protein is a receptor tyrosine kinase that mediates signals by binding to GAS6 and regulates cell survival, proliferation, migration and differentiation. After ligand binding, AXL dimerizes and autophosphorylates, activating downstream molecules, such as PI3 kinase subunits, GRB2, PLCG1, etc. AXL Protein, Human (Biotinylated, HEK293, Fc) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P77877

	AXL Protein, Human (HEK293, His-Avi) Axl; UFO; Axl oncogene; Axl; ARK; JTK11; Tyro7; AI323647; EC 2.7.10; EC 2.7.10.1	Human	HEK293
	AXL protein is a receptor tyrosine kinase that mediates signals by binding to GAS6 and regulates cell survival, proliferation, migration and differentiation. After ligand binding, AXL dimerizes and autophosphorylates, activating downstream molecules, such as PI3 kinase subunits, GRB2, PLCG1, etc. AXL Protein, Human (HEK293, His-Avi) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P77878

	AXL Protein, Human (Biotinylated, HEK293, His-Avi) Axl; UFO; Axl oncogene; Axl; ARK; JTK11; Tyro7; AI323647; EC 2.7.10; EC 2.7.10.1	Human	HEK293
	AXL protein is a receptor tyrosine kinase that mediates signals by binding to GAS6 and regulates cell survival, proliferation, migration and differentiation. After ligand binding, AXL dimerizes and autophosphorylates, activating downstream molecules, such as PI3 kinase subunits, GRB2, PLCG1, etc. AXL Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P77875

	AXL Protein, Human (HEK293, Fc) Axl; UFO; Axl oncogene; Axl; ARK; JTK11; Tyro7; AI323647; EC 2.7.10; EC 2.7.10.1	Human	HEK293
	AXL protein is a receptor tyrosine kinase that mediates signals by binding to GAS6 and regulates cell survival, proliferation, migration and differentiation. After ligand binding, AXL dimerizes and autophosphorylates, activating downstream molecules, such as PI3 kinase subunits, GRB2, PLCG1, etc. AXL Protein, Human (HEK293, Fc) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P704982

	AXL Protein, Human (Biotinylated, HEK293, Fc-Avi) Axl; Axl receptor tyrosine kinase; tyrosine-protein kinase receptor UFO; JTK11; UFO; Axl oncogene; oncogene Axl; Axl transforming sequence/gene;	Human	HEK293

HY-P74406

	AXL Protein, Mouse (HEK293, His-Fc) Tyrosine-protein kinase receptor UFO; Axl oncogene; UFO	Mouse	HEK293
	The AXL protein has predicted roles in various cellular functions, binds to phosphatidylinositol 3-kinase and phosphatidylserine, and serves as a viral receptor. It negatively regulates apoptosis and positively regulates protein kinase B signaling. AXL Protein, Mouse (HEK293, His-Fc) is the recombinant mouse-derived AXL protein, expressed by HEK293 , with C-hFc, C-His labeled tag.

HY-P74407

	AXL Protein, Human (HEK293, His) Tyrosine-protein kinase receptor UFO; Axl oncogene; UFO	Human	HEK293
	AXL protein is a receptor tyrosine kinase that mediates signals by binding to GAS6 and regulates cell survival, proliferation, migration and differentiation. After ligand binding, AXL dimerizes and autophosphorylates, activating downstream molecules, such as PI3 kinase subunits, GRB2, PLCG1, etc. AXL Protein, Human (HEK293, His) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-His labeled tag.

HY-P700585

	AXL Protein, Human (D266N, HEK293, His) Axl receptor tyrosine kinase; tyrosine-protein kinase receptor UFO; JTK11; UFO; Axl oncogene; oncogene Axl; Axl transforming sequence/gene;	Human	HEK293
	AXL protein is a receptor tyrosine kinase that mediates signals by binding to GAS6 and regulates cell survival, proliferation, migration and differentiation. After ligand binding, AXL dimerizes and autophosphorylates, activating downstream molecules, such as PI3 kinase subunits, GRB2, PLCG1, etc. AXL Protein, Human (D266N, HEK293, His) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-10*His labeled tag and D266N mutation.

HY-P700586

	AXL Protein, Human (D266N, HEK293, hFc) Axl receptor tyrosine kinase; tyrosine-protein kinase receptor UFO; JTK11; UFO; Axl oncogene; oncogene Axl; Axl transforming sequence/gene;	Human	HEK293
	AXL protein is a receptor tyrosine kinase that mediates signals by binding to GAS6 and regulates cell survival, proliferation, migration and differentiation. After ligand binding, AXL dimerizes and autophosphorylates, activating downstream molecules, such as PI3 kinase subunits, GRB2, PLCG1, etc. AXL Protein, Human (D266N, HEK293, hFc) is the recombinant human-derived AXL protein, expressed by HEK293 , with C-hFc labeled tag and D266N mutation.

HY-P7623

	AXL Protein, Mouse (HEK293, His) rMuAxl, His; Tyrosine-protein kinase receptor UFO; Axl oncogene; UFO	Mouse	HEK293
	AXL Protein, Mouse (HEK293, His), a recombinant mouse AXL produced in HEK293 cells, has a His tag. AXL is a member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 (GAS6). Anti-cancer activity.

HY-P7622

	AXL Protein, Human (415a.a, HEK293, His) 1 Publications Verification rHuAxl, His; Tyrosine-protein kinase receptor UFO; Axl oncogene; UFO	Human	HEK293
	AXL Protein, Human (HEK293, His), a recombinant human AXL produced in HEK293 cells, has a His tag. AXL is a member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 (GAS6). Anti-cancer activity.

HY-P705572

	AXL Protein, Human (Active, sf9, Flag, Avi) Tyrosine-protein kinase receptor UFO; Axl oncogene; EC:2.7.10.1	Human	Sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-12432S1

Gilteritinib-d8
Gilteritinib-d₈ is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.

HY-15494S1

Picropodophyllin-d6
Picropodophyllin-d₆ (AXL1717-d₆) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

HY-15494S

Picropodophyllin-d3
Picropodophyllin-d₃ (AXL1717-d₃; Picropodophyllotoxin-d₃; PPP-d₃) is the deuterium labeled Picropodophyllin (HY-15494). Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-W706452

Cabozantinib-d4 S-malate
Cabozantinib-d₄ (S-malate) (XL184-d₄ (S-malate); BMS-907351-d₄ (S-malate)) is the deuterium labeled Cabozantinib (S-malate) (HY-12044). Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC₅₀s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-15150S

Bemcentinib-d8

Bemcentinib-d₈ (R428-d₈) is the deuterium labeled Bemcentinib (HY-15150). Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

Host:	Mouse (4) Rabbit (2)
Reactivity:	Human (6) Rat (1) Mouse (2)
Application:	IHC-P (2) ICC/IF (6) IHC-F (1) WB (6) ELISA (6)
Isotype:	IgG (1) IgG1 (2) IgG1,IgG/Kappa (1) IgG/Kappa (1)
Conjugation:	Non-conjugated (6) Biotin (3)
Clonality:	Polyclonal (1) Monoclonal (3) Monoclonal Antibody (1)
Modification:	Unmodified (5)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86126

	Axl Antibody (YA5818) Axl; UFO; Tyrosine-protein kinase receptor UFO; Axl oncogene	WB, IHC-P, ICC/IF, ELISA	Human, Mouse, Rat
	Axl Antibody (YA5818) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Axl.

HY-P85050

	Axl Antibody (YA4742) Axl; UFO; Tyrosine-protein kinase receptor UFO; Axl oncogene	WB, ICC/IF, ELISA	Human
	Axl Antibody (YA4742) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Axl.

HY-P81198

	Axl Antibody Adhesion related kinase; AI323647; Ark; Axl; Axl oncogene; Axl receptor tyrosine kinase; Axl transforming gene; Axl transforming sequence/gene; EC 2.7.10.1; JTK11; Oncogene Axl; Tyro7; Tyrosine protein kinase receptor UFO; Tyrosine-protein kinase receptor UFO; UFO; UFO_HUMAN.	WB, ELISA, IHC-P, IHC-F, ICC/IF	Human, Mouse
	Axl Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Axl.

HY-P84247

	Axl Antibody (YA3944) UFO; JTK11	WB, ICC/IF, ELISA	Human
	Axl Antibody (YA3944) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Axl.

HY-P84247A

	Axl Antibody (YA3944)(PBS only) UFO; JTK11	WB, ICC/IF, ELISA	Human
	Axl Antibody (YA3944) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Axl.

HY-P85881

	Gas6 Antibody (YA5573) GAS6; AxlLG; Growth arrest-specific protein 6; GAS-6; Axl receptor tyrosine kinase ligand	WB, ICC/IF, ELISA	Human
	Gas6 Antibody (YA5573) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Gas6.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Axl

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products